The prognostic value of KRAS mutations in patients with colorectal cancer

Oncology Reports

Volumn 28, Issue 5, 2012, Pages 1579-1584

  Inoue, Yasuhiro ^a   Saigusa, Susumu ^a   Iwata, Takashi ^a   Okugawa, Yoshinaga ^a   Toiyama, Yuji ^a   Tanaka, Koji ^a   Uchida, Keiichi ^a   Mohri, Yasuhiko ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; KRAS p.G13D; Prognostic value

Indexed keywords

ADENINE; CETUXIMAB; CYTOSINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GUANINE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; THYMINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL EVALUATION; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; JAPANESE; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, RAS; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 84866450315     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1974     Document Type: Article

References (38)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
2. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
3. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786, 2007. (Pubitemid 350086481)
4. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
5. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
6. Cappuzzo F, Finocchiaro G, Rossi E, et al: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19: 717-723, 2008. (Pubitemid 351461042)
7. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008. (Pubitemid 351171687)
8. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169, 2007. (Pubitemid 46625066)
9. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237, 2007. (Pubitemid 47325606)
10. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
11. De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304: 1812-1820, 2010.
12. Tejpar S, Bokemeyer C, Celik I, Schlichting M, Sartorius U and Van Cutsem E: Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 29: 3511, 2010.
13. Peeters M, Douillard JY, Cutsem E, et al: Evaluation of individual codon 12 and 13 mutant (MT) KRAS alleles as prognostic and predictive biomarkers of response to panitumumab (pmab) in patients with metastatic colorectal cancer (mCRC). Eur J Cancer 47 (Suppl 2): 16, 2011.
14. Dix BR, Robbins P, Soong R, et al: The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 59: 747-751, 1994.
15. Iniesta P, Caldés T, Vega FJ, et al: Prevalence of p53 overexpression or mutations, but not K-ras mutations, in recurrent patients affected by colorectal carcinoma. Int J Oncol 7: 319-325, 1995.
16. Andersen SN, Lovig T, Breivik J, et al: K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 32: 62-69, 1997. (Pubitemid 27026469)
17. Tortola S, Marcuello E, Gonzalez I, et al: p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 17: 1375-1381, 1999. (Pubitemid 29220842)
18. Hirvikoski P, Auvinen A, Servomaa K, et al: K-ras and p53 mutations and overexpressions as prognostic factors in female rectal carcinoma. Anticancer Res 19: 685-691, 1999. (Pubitemid 29168316)
19. Esteller M, Gonzalez S, Risques RA, et al: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19: 286-288, 2001.
20. Laurent-Puig P, Olschwang S, Delattre O, et al: Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 102: 1136-1141, 1992.
21. Bell SM, Scott N, Cross D, et al: Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104: 57-64, 1993. (Pubitemid 23040006)
22. Lee JC, Wang ST, Lai MD, et al: K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 16: 3839-844, 1996.
23. Ahnen DJ, Feigl P, Quan G, et al: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58: 1149-1158, 1998. (Pubitemid 28183202)
24. Bouzourene H, Gervaz P, Cerottini JP, et al: p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36: 1008-1015, 2000. (Pubitemid 30316426)
25. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85: 692-696, 2001. (Pubitemid 32929467)
26. Benhattar J, Losi L, Chaubert P, et al: Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 104: 1044-1048, 1993. (Pubitemid 23090756)
27. Cerottini JP, Caplin S, Saraga E, et al: The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 175: 198-202, 1998. (Pubitemid 28173710)
28. Span M, Moerkerk PTM, De Goeij AFPM and Arends JW: A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 69: 241-245, 1996. (Pubitemid 26233305)
29. Pajkos G, Kiss I, Sandor J, et al: The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res 20: 1695-1701, 2000. (Pubitemid 30628188)
30. Samowitz WS, Curtin K, Schaffer D, et al: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9: 1193-1197, 2000.
31. Al-Mulla F, Going JJ, Sowden ET, et al: Heterogeneity of mutant versus wild-type in primary and metastatic colorectal carcinomas, and association of codon 12 valine with early mortality. J Pathol 185: 130-138, 1998. (Pubitemid 28270924)
32. Uetake H, Watanabe T, Yoshino T, et al: Clinicopathological features of patients with colorectal cancer among KRAS wild type p.G13D and other mutations: results from a multicenter, cross-sectional study by the Japan Study Group of KRAS Mutation in Colorectal Cancer. J Clin Oncol 29: 3605, 2011.
33. Yokota T, Ura T, Shibata N, et al: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104: 856-862, 2011.
34. Schubbert S, Shannon K and Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308, 2007. (Pubitemid 46480970)
35. Harari PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11: 689-708, 2004.
36. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours (Review). Int J Oncol 7: 413-421, 1995.
37. Andreyev HJ, Norman AR, Cunningham D, Oates JR and Clarke PA: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684, 1998. (Pubitemid 28222141)
38. Guerrero S, Casanova I, Farré L, Mazo A, Capellà G and Mangues R: K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60: 6750-6756, 2000.